Drug Profile
Research programme: peptide therapeutics - Soricimed
Alternative Names: SOR-C27; SOR-N54; Soricidin-derived C-series peptide therapeutics; Soricidin-derived N-series peptide therapeuticsLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Soricimed Biopharma
- Class Drug conjugates; Non-opioid analgesics; Peptides
- Mechanism of Action Apoptosis stimulants; Sodium channel antagonists; TRPV6 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Ovarian cancer; Pain; Prostate cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Breast-cancer in Canada (IV, Infusion)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Ovarian-cancer in Canada (IV, Infusion)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Pain in Canada